

03.09.2025

To National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: SaiLife	To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001 BSE Scrip Code: 544306
---	--

Dear Sir,

Subject: Resolutions No. 4 and 5: Re-appointment of Mr. Krishnam Raju Kanumuri (“Mr. Krishnam Raju”) as MD and CEO of the Company and approval for revision in remuneration payable to Mr. Krishnam Raju as MD and CEO of the Company.

With reference to the resolutions proposed to be passed at the 26th annual general meeting of the Company, as set out in notice dated August 7, 2025 (“**Notice**”) for the captioned matter, and the revised voting recommendations issued by the proxy advisory Institutional Investor Advisory Services (“**IiAS**”) in relation to such resolutions, Sai Life Sciences Limited (“**Company**” or “**we**”) would like to disclose that the Company has provided certain clarifications / comments to IiAS, as set out in the below annexure.

This is for your information and records.

Thank you.

For Sai Life Sciences Limited

Runa Karan
Company Secretary & Compliance Officer
Membership No.: A13721

Sai Life Sciences Limited (CIN: L24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey
#133, Gachibowli Miyapur Road,
Gachibowli, Hyderabad – 500032,
Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally
(V), Shameerpet Mandal, Medchal-Malkajgiri
(Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com

Annexure A

Response issued to IiAS

Sai Life Sciences Limited has received the updated proxy advisory report from Institutional Investor Advisory Services (“IiAS”) dated September 2, 2025 (“Report”) and we thank you for taking on record our submissions relating to the aggregate pay of Krishnam Raju Kanumuri as it relates to the AGM notice items 4 & 5.

With regards to the basis of computation of the Performance Linked Incentive (“PLI”), we had pointed out that the Report has used the TTM PBT for the purpose of computing the estimated PLI (*Para 2(1) of our response*). However, the estimated FY26 PLI payable per IiAS, based on the TTM numbers shown in Exhibit 5, continues to be computed based on the PBT numbers as opposed to the net profits as defined in the AGM notice.

A summary computation of the estimated PLI for the TTM assuming a PLI payout of 3.25% to 3.5% is provided below for clarity. This table summarizes the impact of computing the PLI basis the PBT as opposed to the intended payout basis the PAT.

Rs. Million	FY 25	TTM	PLI @ 3.25%	PLI @ 3.5%
Standalone PBT	2,317.1	3,248.5	105.6	113.7
Standalone PAT	1,734.6	2,432.1	79.0	85.1
Difference			26.5	28.6

As noted above, the above computation done on PBT shows a significantly higher PLI in the range of INR 26.5 Million to INR 28.6 Million.

We therefore would request you to share our response with all your subscribers and persons to whom the original Report has been circulated to. We also sincerely urge you to amend your recommendations given significant changes to the numbers based on the above and issue a revised report under intimation to us.

The Company will also be disclosing these clarifications on the stock exchanges (BSE Limited and National Stock Exchange of India Limited) for the benefit of all shareholders

Thanking you,

Yours faithfully,
For **Sai Life Sciences Limited**

Runa Karan
Company Secretary and Compliance Officer

Sai Life Sciences Limited (CIN: L24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey
#133, Gachibowli Miyapur Road,
Gachibowli, Hyderabad – 500032,
Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally
(V), Shameerpet Mandal, Medchal-Malkajgiri
(Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com